Abstract:Background Invasive fungal infection (IFI) is a common and fatal complication in neutropenic patients with hematological malignancy. Empirical antifungal therapy is widely used in practice due to the difficulty of pathogens determination and illness of the hosts. The aim of this study was to evaluate the efficacy and safety of itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematologic malignancies.Methods Two hundred and seventy-four patients with hematologic malignancies who had suspected fungal infections were enrolled in 18 centers across China between April 2008 and April 2009. Empirical antifungal therapy with intravenous itraconazole 200 mg twice daily was given for the first two days, followed by 200 mg once daily for the next 12 days. Oral itraconazole solution was sequential for follow-up therapy if necessary. Five composite end points were evaluated for the response, which was more restrictive and adopted for the first time in such study in China.Results The intent-to-treat analysis included data from 274 patients (full analysis set, FAS), of whom 248 were included as the per-protocol population (PPS). As the composite end point of five indices was concerned, the overall response rate was 43.4%. Seperately, defervescence was achieved in 90% of patients in which 55.5% occured during neutropenia. The mean time to defervescence was 2.71 days. Absence of breakthrough IFI during drug administration or within the first 7 days after study completion was observed in 71.5% of patients. Fifty-five point five percent patients with IFI at baseline was successfully treated. Ninety point five percent patients survived for at least 7 days after completing the study. PPS analysis revealed that the duration of neutropenia >= 10 days was a statistically significant negative predictor for the response. The withdrawal rate due to drug-related toxicity or lack of efficacy was 11.0%. The incidence of adverse events was 22.6%, in which 11.6% was study drug related. The most frequent adverse events were mild to moderate liver toxicity.Conclusion ltraconazole shows desirable efficacy and safety as empirical antifungal therapy for febrile neutropenic patients with hematologic malignancies. Chin Med J 2011;124(22):3670-3675

Changes of intestinal microflora and immune function after chemotherapy maybe associated with fever in patients with neutropenia

[Following-Up of Nosocomial Lower Respiratory Infection in Patients with Hematological Malignancy after Chemotherapy].

Clinical Analysis of High-Risk Primary and Metastatic Breast Cancer Patients with Neutropenia and Fever after High-Dose Chemotherapy

Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment

Efficacy and Safety of Itraconazole As Empirical Antifungal Therapy in Febrile Neutropenic Patients with Hematologic Malignancies: an Open-Lable, Multicenter, Observational Trial in A Chinese Cohort

Effects of chemotherapy on humoral immunity of patients with cancer

Specific gut microbiota changes heralding bloodstream infection and neutropenic fever during intensive chemotherapy

Analysis of NK/T and Treg cell in peripheral blood of patients with different malignancies during the chemotherapy

A Study of Novel Febrile Neutropenia Risk Factors Related to Bone Marrow or Immune Suppression, Barrier Function, and Bacterial Flora.

Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia

Etiological analysis of nosocomial infections in patients with acute leukemia and clinical treatment

Risk factors for nosocomial infections in rectal carcinoma patients undergoing chemotherapy

16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation

Outcomes in 102 patients that present to the emergency department with chemotherapy-induced febrile neutropenia

Changes of immune pattern in lung cancer patients before and after chemotherapy

[Influence of FOLFOX Regimen on the Immunologic Function in Patients with Advanced Colorectal Cancer].

Gut microbiome in association with chemotherapy‐induced toxicities among patients with breast cancer

RETRACTED ARTICLE: Neutropenia and Invasive Fungal Infection in Patients with Hematological Malignancies Treated with Chemotherapy: a Multicenter, Prospective, Non-Interventional Study in China

[Microorganisms cultured from sputum and blood in association with episodes of fever during anti-cancer therapy in patients with lung cancer]

Preneutropenic Fever in Patients With Hematological Malignancies: A Novel Target for Antimicrobial Stewardship

Changes of Intestinal Microbiota in Ovarian Cancer Patients Treated with Surgery and Chemotherapy